Cargando…
Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
BACKGROUND AND AIM: The progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) is believed to be the driver for future development of fibrosis and cirrhosis. Nevertheless, there remains a clear deficit in non-invasive methods for the diagnosis of NASH. The a...
Autores principales: | Daher, Saleh, Lev Cohen, Namma, Massarwa, Muhammad, Mahamid, Mahmud, Nasser, Mira, Hazou, Wadi, Oren, Rani, Safadi, Rifaat, Khoury, Tawfik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267957/ https://www.ncbi.nlm.nih.gov/pubmed/30500848 http://dx.doi.org/10.1371/journal.pone.0207479 |
Ejemplares similares
-
Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
por: Safadi, Rifaat, et al.
Publicado: (2021) -
Endoscopic Ultrasound‐Guided Angiotherapy for Gastric Varices: A Single Center Experience
por: Khoury, Tawfik, et al.
Publicado: (2018) -
Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer‐BioNTech COVID‐19 Vaccine in Medical Employees
por: Shafrir, Asher, et al.
Publicado: (2022) -
The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice
por: Fishman, Pnina, et al.
Publicado: (2019) -
SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers
por: Khalaileh, Abed, et al.
Publicado: (2023)